Lexicon Pharmaceuticals (LXRX) EBIAT (2024 - 2025)
Lexicon Pharmaceuticals (LXRX) has disclosed EBIAT for 4 consecutive years, with -$12.8 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT rose 80.3% to -$12.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$99.6 million, a 50.31% increase, with the full-year FY2011 number at -$116.2 million, down 14.19% from a year prior.
- EBIAT was -$12.8 million for Q3 2025 at Lexicon Pharmaceuticals, down from $3.3 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $3.3 million in Q2 2025 to a low of -$64.8 million in Q3 2024.